CERTIS USA LLC is a company based out of 818 E EXPRESSWAY 83, WESLACO, Texas, United States.

Drake Extrusion is North America’s leading manufacturer of colored filament yarn and staple fiber. For over two decades, the name Drake has led the colored polypropylene fiber industry in North America, with research and development based on two continents. Our sister companies IFG Drake, IFG Asota and IFG Exelto have advanced development in high-performance fibers. Located in North America’s textile heartland, we have an unrivaled reputation for excellent customer service, and offer you the personalized service and flexibility of a custom supplier, backed by the resources of our parent company, International Fibres Group. Markets we serve, but are not limited to, are: - Automotive - Home Furnishings - Floor Coverings - GeoTextile - Specialty/Niche Markets

ALLENS PHARMASERV INC is a hospital & health care company based out of PO BOX 2208, YOUNGSTOWN, Ohio, United States.

Reparex Fabricating Systems is a glass, ceramics & concrete company based out of Center Dr Bldg D8, Latrobe, Pennsylvania, United States.

Our Focus Dunn Regulatory Associates, LLC’s focus is to provide superior regulatory strategy, US Agent Services, and regulatory document preparation for the development of Rx and OTC pharmaceuticals, biopharmaceuticals, devices, and cosmetics. Using an experienced based approach that provides strategic, scientific and regulatory integration, our firm’s goal is to streamline your development efforts. The firm’s focus includes:  Developing pragmatic approaches to regulatory issues  Developing concise and thorough regulatory strategies  Negotiating with the FDA and EU  US Agent services including IND maintenance  Writing, managing and reviewing all modules of the CTD, IB, and meeting packages  Utilization of expedited regulatory pathways including Breakthrough therapy  Strategic product placement  Preparation of Integrated Development Plans

60 years of excellence in development and production of custom coatings, paints and other finishes for industrial, commercial, and residential applications.

Blue Grass Chemical Specialties LLC celebrated 50 years in business in 2019. We are a modern chemical manufacturer, located in New Albany, Indiana, just across the Ohio River from Louisville, Kentucky. Our facility is diverse and flexible, allowing prompt and cost effective production whether it is a simple blending operation, or a complex multi stage precipitation. WHAT WE DO: Blue Grass specializes in aqueous inorganic metal salt solutions and makes some precipitated products along with performing extensive toll manufacturing for other companies. Metal salts are a field in which Blue Grass is a recognized leader. Catalyst, Oil and Gas, Agriculture, Metal Finishing, Photographic, and Electronics are but a few of the industries which rely on our Metal Salt Products. Our modern, well equipped laboratory is professionally staffed allowing us to tailor our metal salt solutions to our customer’s exact specifications. WHY WE DO IT: Customer service is what our business is all about. We work with our customers through every step of a products development to assure that our customer’s exact requirements are met. Blue Grass Chemical Specialties can develop and produce your complex chemical needs safely, efficiently, on time, and on budget. Our modern facilities and professional expertise assure quality control from start to finish. So when you need specialized chemical solutions, give us a call. We’ll show you our formula for success.

Wall Firma Inc. is a chemicals company based out of United States.

Advancing regenerative medicine through the development of a natural biomaterial that restores mother nature’s template to treat disease and injury. ECM scaffolds, in solid form, have been successfully used in more than 10 million human patients to repair a variety of body systems such as musculoskeletal tissues, cardiovascular structures, and non-healing skin wounds, among others. These products have all received FDA clearance. ECM Therapeutics'​ patented ECM hydrogel technology allows for expanded, less invasive applications in multiple disease areas. The first clinical product, EsophaGel, treats Barrett’s esophagus, a precancerous condition that currently has no effective therapy.

Invirsa is developing a small molecule (INV-102) that promotes both DNA repair and the innate immune response to infection and injury. These actions lead to enhanced wound healing associated with reductions in inflammation and viral replication. INV-102 has demonstrated unprecedented efficacy in animal models of ocular sulfur mustard gas injury. Sulfur mustard is a dangerous chemical weapon, and INV-102 is the first drug to show promise in preventing its long-term effects. There is no current FDA approved therapy for this injury. In September of 2020, Invirsa received a $29.6M BARDA award ($14.4M plus $15.2M in milestones) to support the clinical development of INV-102 for the treatment of ocular sulfur mustard gas injury and other ocular injuries associated with DNA damage. The award covers development through Phase 3 clinical trials. Invirsa’s initial commercial focus for INV-102 will be infectious keratoconjunctivitis as there is no treatment for the viral form of this disease which comprises 80% of all cases. INV-102 has demonstrated clear efficacy in animal models of infectious conjunctivitis.